PBAC March 2021 Meeting Agenda Summary for rare and less common cancers
Your comments are welcome whether you are a patient, carer, member of the public, health professional or member of a consumer interest group.
If you or someone you know is affected by any of the following rare or less common cancer diagnoses, or you have anything you’d like to add in support of these medicines being listed on the PBAC, please contact the Patient Support Team on 1800 257 600 or go straight to the PBAC portal: Click Here
- AVELUMAB (Bavencio) – Request: the listing for the treatment of locally advancedat a late stage, far along (Stage III) or metastatic (Stage IV) urothelial carcinomacancer arising from tissues that line organs.
- BRENTUXIMAB VEDOTIN (ADCETRIS)® – Request: the listing for the first-line treatment of CD30 positive peripheral T-cell lymphoma.
- DECITABINE AND CEDAZURIDINE (Inqovi) – Request: the listing for the treatment of high-risk Myelodysplastic syndromes (MDS) and chronic myelomonocytic leukaemia (CMML).
- ENCORAFENIB (Braftovi) – Request: the listing for the treatment of BRAF V600E-variant metastatic (Stage IV) colorectal cancer.
- GEMTUZUMAB OZOGAMICIN (Mylotarg) – Request: the listing for the treatment of de novo CD33-positive AML (Acute myeloid leukaemia)
- NIRAPARIB (Zejula)® – Request: the listing for the treatment of platinum-sensitive, relapsed, high grade serous ovarian, fallopian tube or primary peritoneal cancer. Ovarian, fallopian tube, or primary peritoneal cancer.
- NIVOLUMAB with IPILIMUMAB (Opdivo and Yervoy) – Request: the listing for the use of nivolumab in combination with ipilimumab for the treatment of Malignant pleural mesothelioma.
- PEMBROLIZUMAB (Keytruda) – Request: the listing for the treatment of metastatic (Stage IV) mismatch repair deficient colorectal cancer.
- RIPRETINIB (Qinlock) – Request: the listing for the treatment of metastatic or unresectable malignant Gastrointestinal stromal tumour (GIST).
- VENETOCLAX (Venclexta) – Request: the listing for the treatment of Acute myeloid leukaemia (AML).